Stocktoria
Ensysce Biosciences, Inc. ENSC
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-12-01
Ensysce Biosciences, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5.1M | $5.2M | $2.2M | $2.5M | $3.5M |
| R&D expense | $10.4M | $7.2M | $7.6M | $19.8M | $4.7M |
| SG&A expense | — | — | — | — | $18.7M |
| Operating income | -$10.2M | -$6.7M | -$10.7M | -$24.2M | -$19.9M |
| Interest expense | — | — | $353,945 | $109,525 | $1.3M |
| Operating cash flow | -$7.8M | -$7.5M | -$10.8M | -$17.9M | -$8.2M |
| Free cash flow | -$7.9M | — | — | — | — |
| Cash & equivalents | $4.3M | $3.5M | $1.1M | $3.1M | $12.3M |
| Total assets | $7.5M | $5.6M | $2.7M | $5.9M | $16.4M |
| Total liabilities | $4.6M | $2.2M | $3.4M | $9.9M | $24.6M |
| Shareholders' equity | $3.2M | $3.7M | -$651,267 | -$4.0M | -$8.2M |
| EPS (diluted) | $-3.98 | $-11.45 | $-70.40 | $-139.42 | $-1.48 |
Source: SEC EDGAR filings · CIK 0001716947 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.